SCHEDULE: Evogene Ltd. Shareholder Update: Leon Recanati Acquires More Shares

Evogene Ltd. announces an amendment to its Schedule 13D filing, detailing Leon Recanati's acquisition of an additional 1,260,000 ordinary shares through at-the-market offerings.

Summary

• Leon Recanati has amended his Schedule 13D filing to reflect the acquisition of an additional 1,260,000 ordinary shares in Evogene Ltd.
• The purchases occurred on August 4, 2026 (800,000 shares at $0.50 each) and August 11, 2026 (460,000 shares at $0.635 each).
• These acquisitions were made through block trades executed via Evogene's at-the-market offering facility, with A.G.P./Alliance Global Partners acting as the sales agent.
• The total consideration for these shares was approximately $692,100.
• Following these transactions, Leon Recanati beneficially owns 1,354,836 ordinary shares, representing 8.6% of the outstanding shares.
• This ownership includes 10,950 ordinary shares underlying currently exercisable options.
• The filing is an amendment to a previously filed Schedule 13D, with this amendment specifically updating the description of the purchase method.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily reflecting routine updates on share acquisitions rather than significant strategic shifts or performance indicators.

Positives

• Increased beneficial ownership by a significant shareholder, Leon Recanati, indicating continued confidence in the company.
• Acquisitions were made through the company's at-the-market offering facility, suggesting efficient execution of share purchases.
• The shareholder's stake has increased to 8.6% of outstanding shares, consolidating ownership.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Evogene Ltd.
• The purchase prices, particularly the $0.635 per share on August 11, 2026, are relatively low, which could be a concern if the market price is higher or expected to rise significantly.

Risks

• The filing itself does not introduce new risks but is an update to existing disclosures.
• Potential for future share price volatility related to the ongoing at-the-market offering facility.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from management regarding future performance. It primarily details past transactions.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for significant shareholders accumulating or adjusting their stakes. The use of an at-the-market offering facility by Evogene Ltd. is a standard capital markets tool, often employed by growth-oriented companies to raise funds efficiently. The specific details of these transactions provide insight into the shareholder's ongoing investment strategy.

Stakeholder Impact

• Shareholders: The increased stake by a significant holder may signal confidence, potentially influencing market perception. The use of ATM facilities can dilute existing shareholders if not managed effectively.
• Management: The filing confirms ongoing share acquisition activities by a key investor.
• Creditors: No direct impact indicated.

Next Steps

• Continued monitoring of Leon Recanati's beneficial ownership and any future amendments to Schedule 13D.
• Observation of Evogene Ltd.'s utilization of its at-the-market offering facility.

Key Dates

Keywords

Evogene Ltd., Schedule 13D, Shareholder, Beneficial Ownership, At-the-Market Offering, Block Trades, Ordinary Shares, Leon Recanati